Introduction of indices of clinical insulin resistance / sensitivity under significant urinary glucose excretion - indices of insulin sensitivity under using SGLT-2 inhibitors (ISUUSI)

Department of Endocrinology and Diabetes Saitama Medical Center, Saitama Medical University0 个研究点目标入组 20 人开始时间: 2014年7月15日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Under the treatment with insulin 2) Type 1 diabetic subjects or diabetic subjects who have HbA1c more than or equal to 8.0 % or who need admission because of diabetic ketoacidosis or extreme hyperglycemia. 3) Subjects who are treated with sulfonylureas (i.e. glibenclamide, glimepiride, or gliclazide). 4) Subjects with nephrotic syndrome (urine protein more than or equal to 3.5g/day and serum protein less than or equal to 6.0 g/dl [or serum albumin less than or equal to 3.0 g/dl]. 5) Subjects who are taking steroids, immune suppression medication, antifungal medication of azoles. HIV protease inhibitors 6) Subjects who had brain stroke or acute coronary syndrome within 6 months before enrollment. 7) Subjects with severe heart failure (NYHA class 3 or higher), severe arrhythmia (frequent atrial or ventral arrhythmia, continuous ventricular tachycardia, severe atrial tachycardia, atrial fibrillation or flutter with severe tachycardia, sick sinus syndrome or atrial-ventral block with severe bradycardia). 8) Subjects who have AST or ALT more than 5 times of upper normal limit of their institute 9) Subjects with malignancy 10) Subjects who are pregnant or who have intention to be pregnant 11) Subjects with other situations under which a doctor in charge decides that subjects are not eligible for this study.

发起方

Department of Endocrinology and Diabetes Saitama Medical Center, Saitama Medical University